DOCSLIB.ORG

Drug Monographs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Drug Monographs Subscription of Clinical Key Nursing for the year 2017 Nursing Faculty - Drug Monographs SN Drug Name On CK 1 A Thru Z 2013 2 A Thru Z Advantage 2013 3 A Thru Z Select 2013 4 Abacavir 09-05-14 5 Abacavir; Lamivudine, 3TC 08-11-13 6 Abacavir; Lamivudine, 3TC; Zidovudine, ZDV 08-11-13 7 Abarelix 04-04-14 8 Abatacept 2013 9 Abciximab 2013 10 Abetimus 2013 11 Abiraterone 30-01-14 12 AbobotulinumtoxinA 2013 13 Absorbable Gelatin Sponge 2013 14 Acamprosate 2013 15 Acarbose 09-05-14 16 Acebutolol 2013 17 Acerflex 2013 18 Acetaminophen 24-01-14 19 Acetaminophen; Aspirin, ASA; Caffeine 2013 20 Acetaminophen; Brompheniramine; Dextromethorphan; Pseudoephedrine 2013 21 Acetaminophen; Brompheniramine; Pseudoephedrine 2013 22 Acetaminophen; Butalbital 24-01-14 23 Acetaminophen; Butalbital; Caffeine 24-01-14 24 Acetaminophen; Butalbital; Caffeine; Codeine 24-01-14 25 Acetaminophen; Caffeine 2013 26 Acetaminophen; Caffeine; Chlorpheniramine; Hydrocodone; Phenylephrine 2013 27 Acetaminophen; Caffeine; Dihydrocodeine 24-01-14 28 Acetaminophen; Caffeine; Magnesium Salicylate; Phenyltoloxamine 2013 29 Acetaminophen; Caffeine; Phenyltoloxamine; Salicylamide 24-01-14 30 Acetaminophen; Chlorpheniramine 2013 31 Acetaminophen; Chlorpheniramine; Dextromethorphan 2013 32 Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine 2013 33 Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine 2013 34 Acetaminophen; Chlorpheniramine; Phenylephrine 2013 35 Acetaminophen; Chlorpheniramine; Phenylephrine; Phenyltoloxamine 2013 36 Acetaminophen; Chlorpheniramine; Pseudoephedrine 2013 37 Acetaminophen; Clemastine; Pseudoephedrine 2013 38 Acetaminophen; Codeine 2013 39 Acetaminophen; Dexbrompheniramine; Pseudoephedrine 2013 40 Acetaminophen; Dextromethorphan 2013 41 Acetaminophen; Dextromethorphan; Doxylamine 2013 42 Acetaminophen; Dextromethorphan; Doxylamine; Pseudoephedrine 2013 Page 1 of 70 Subscription of Clinical Key Nursing for the year 2017 Nursing Faculty - Drug Monographs SN Drug Name On CK 43 Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine 2013 44 Acetaminophen; Dextromethorphan; Guaifenesin; Pseudoephedrine 2013 45 Acetaminophen; Dextromethorphan; Phenylephrine 2013 46 Acetaminophen; Dextromethorphan; Pseudoephedrine 2013 47 Acetaminophen; Dichloralphenazone; Isometheptene 2013 48 Acetaminophen; Diphenhydramine 2013 49 Acetaminophen; Diphenhydramine; Pseudoephedrine 2013 50 Acetaminophen; Guaifenesin; Phenylephrine 2013 51 Acetaminophen; Hydrocodone 14-02-14 52 Acetaminophen; Melatonin 2013 53 Acetaminophen; Oxycodone 28-03-14 54 Acetaminophen; Pamabrom 2013 55 Acetaminophen; Pamabrom; Pyrilamine 2013 56 Acetaminophen; Pentazocine 24-01-14 57 Acetaminophen; Phenyltoloxamine 2013 58 Acetaminophen; Propoxyphene 2013 59 Acetaminophen; Pseudoephedrine 2013 60 Acetaminophen; Tramadol 24-01-14 61 Acetazolamide 07-03-14 62 Acetic Acid, Glacial 2013 63 Acetic Acid; Hydrocortisone 2013 64 Acetic Acid; Oxyquinoline; Ricinoleic Acid 2013 65 Acetohexamide 09-05-14 66 Acetohydroxamic Acid 2013 67 Acetophenazine 2013 68 Acetylcholine Chloride 2013 69 Acetylcysteine 2013 70 Acidophilus with Pectin 2013 71 Acidulated Phosphate Fluoride 2013 72 Acitretin 2013 73 Acrivastine; Pseudoephedrine 2013 74 Acyclovir 14-04-14 75 Acyclovir; Hydrocortisone 06-09-13 76 Adalimumab 09-05-14 77 Adapalene 2013 78 Adapalene; Benzoyl Peroxide 2013 79 Adefovir 2013 80 ADEKs 2013 81 ADEKs Drops 2013 82 Adenosine 27-11-13 83 Adenovirus vaccine 2013 84 Ado-Trastuzumab emtansine 17-04-14 85 Advanced NatalCare 2013 Page 2 of 70 Subscription of Clinical Key Nursing for the year 2017 Nursing Faculty - Drug Monographs SN Drug Name On CK 86 Advanced-RF NatalCare 2013 87 Advera 2013 88 Afatinib 17-04-14 89 Aflibercept 2013 90 A-Free Prenatal 2013 91 Agalsidase Alfa 2013 92 Agalsidase Beta 2013 93 Airborne Effervescent Health Formula 2013 94 Airborne Jr. Effervescent Health Formula 2013 95 Airborne Sore Throat Gummi Lozenges 2013 96 Albendazole 10-01-14 97 Albiglutide 09-05-14 98 Albumin 2013 99 Albuterol 18-04-14 100 Albuterol; Ipratropium 14-04-14 101 Alcaftadine 2013 102 Alclometasone 2013 103 Aldesleukin, IL-2 26-12-13 104 Alefacept 2013 105 Alemtuzumab 09-05-14 106 Alendronate 2013 107 Alendronate; Cholecalciferol 2013 108 Alfentanil 2013 109 Alfimeprase 2013 110 Alfuzosin 05-05-14 111 Alglucerase 2013 112 Alglucosidase alfa 2013 113 Alicaforsen 2013 114 Aliminase 2013 115 Aliskiren 08-11-13 116 Aliskiren; Amlodipine 22-11-13 117 Aliskiren; Amlodipine; Hydrochlorothiazide, HCTZ 08-11-13 118 Aliskiren; Hydrochlorothiazide, HCTZ 08-11-13 119 Aliskiren; Valsartan 09-05-14 120 Alitretinoin 2013 121 Alkavite 2013 122 Allbee C-800 2013 123 AllBee Plus Vitamin C 2013 124 Allopurinol 2013 125 Almotriptan 2013 126 Aloe Polysaccharide; Iodoquinol 2013 127 Alogliptin 09-05-14 128 Alogliptin; Metformin 22-11-13 Page 3 of 70 Subscription of Clinical Key Nursing for the year 2017 Nursing Faculty - Drug Monographs SN Drug Name On CK 129 Alogliptin; Pioglitazone 09-05-14 130 Alosetron 19-09-13 131 Alpha lipoic acid 2013 132 Alpha-1-proteinase Inhibitor 2013 133 Alprazolam 28-03-14 134 Alprostadil 04-10-13 135 Alteplase, tPA 25-10-13 136 Altretamine 2013 137 Aluminum Acetate, Burow's Solution 2013 138 Aluminum Chloride 2013 139 Aluminum Hydroxide 08-11-13 140 Aluminum Hydroxide; Magnesium Carbonate 08-11-13 141 Aluminum Hydroxide; Magnesium Hydroxide 08-11-13 142 Aluminum Hydroxide; Magnesium Hydroxide; Simethicone 08-11-13 143 Aluminum Hydroxide; Magnesium Trisilicate 08-11-13 144 Alvimopan 2013 145 Amantadine 2013 146 Ambenonium Chloride 2013 147 Ambrisentan 19-09-13 148 Amcinonide 2013 149 Amediplase 2013 150 Amifostine 2013 151 Amikacin 09-05-13 152 Amiloride 09-05-14 153 Amiloride; Hydrochlorothiazide, HCTZ 2013 154 Aminate Fe 2013 155 Aminobenzoate Potassium 2013 156 Aminocaproic Acid 2013 157 Aminoglutethimide 2013 158 Aminolevulinic Acid 2013 159 Aminosalicylate sodium, Aminosalicylic acid 05-05-14 160 Aminosyn 10% 2013 161 Aminosyn 3.5% 2013 162 Aminosyn 3.5% M 2013 163 Aminosyn 5% 2013 164 Aminosyn 5% Sulfite-Free 2013 165 Aminosyn 7% 2013 166 Aminosyn 7% with Electrolytes 2013 167 Aminosyn 7% with Electrolytes Sulfite-Free 2013 168 Aminosyn 8.5% 2013 169 Aminosyn 8.5% Sulfite-Free 2013 170 Aminosyn 8.5% with Electrolytes Sulfite-Free 2013 171 Aminosyn II 10% Sulfite-Free 2013 Page 4 of 70 Subscription of Clinical Key Nursing for the year 2017 Nursing Faculty - Drug Monographs SN Drug Name On CK 172 Aminosyn II 10% with Electrolytes 2013 173 Aminosyn II 3.5% 2013 174 Aminosyn II 5% 2013 175 Aminosyn II 7% 2013 176 Aminosyn II 8.5% 2013 177 Aminosyn 10% Sulfite-Free 2013 178 Aminosyn 3.5% M Sulfite-Free 2013 179 Aminosyn 3.5% Sulfite-Free 2013 180 Aminosyn 7% Sulfite-Free 2013 181 Aminosyn 8.5% with Electrolytes 2013 182 Aminosyn -HBC 7% 2013 183 Aminosyn -HBC 7% Sulfite-Free 2013 184 Aminosyn II 2013 185 Aminosyn II 10% 2013 186 Aminosyn II 3.5% in Dextrose 25% 2013 187 Aminosyn II 8.5% Sulfite-Free 2013 188 Aminosyn -PF 10% 2013 189 Aminosyn -RF 5.
Load more

Recommended publications
  • Endothelin System and Therapeutic Application of Endothelin Receptor
    xperim ACCESS Freely available online & E en OPEN l ta a l ic P in h l a C r m f o a c l a o n l o r g u y o J Journal of ISSN: 2161-1459 Clinical & Experimental Pharmacology Research Article Endothelin System and Therapeutic Application of Endothelin Receptor Antagonists Abebe Basazn Mekuria, Zemene Demelash Kifle*, Mohammedbrhan Abdelwuhab Department of Pharmacology, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia ABSTRACT Endothelin is a 21 amino acid molecule endogenous potent vasoconstrictor peptide. Endothelin is synthesized in vascular endothelial and smooth muscle cells, as well as in neural, renal, pulmonic, and inflammatory cells. It acts through a seven transmembrane endothelin receptor A (ETA) and endothelin receptor B (ETB) receptors belongs to G protein-coupled rhodopsin-type receptor superfamily. This peptide involved in pathogenesis of cardiovascular disorder like (heart failure, arterial hypertension, myocardial infraction and atherosclerosis), renal failure, pulmonary arterial hypertension and it also involved in pathogenesis of cancer. Potentially endothelin receptor antagonist helps the treatment of the above disorder. Currently, there are a lot of trails both per-clinical and clinical on endothelin antagonist for various cardiovascular, pulmonary and cancer disorder. Some are approved by FAD for the treatment. These agents are including both selective and non-selective endothelin receptor antagonist (ETA/B). Currently, Bosentan, Ambrisentan, and Macitentan approved
    [Show full text]
  • Novel Antagonists for the Human Adenosine
    UvA-DARE (Digital Academic Repository) Novel antagonists for the human adenosine A2A and A3 receptor via purine nitration: synthesis and biological evaluation of C2-substituted 6- trifluoromethylpurines and 1-deazapurines Koch, M. Publication date 2011 Document Version Final published version Link to publication Citation for published version (APA): Koch, M. (2011). Novel antagonists for the human adenosine A2A and A3 receptor via purine nitration: synthesis and biological evaluation of C2-substituted 6-trifluoromethylpurines and 1- deazapurines. General rights It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons). Disclaimer/Complaints regulations If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible. UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl) Download date:05 Oct 2021 Novel antagonists for the human adenosine A Novel antagonists for the human adenosine Uitnodiging Novel antagonists for the voor het bijwonen van human adenosine de openbare verdediging van het proefschrift van A2A and A3 receptor via purine nitration Melle Koch op vrijdag 21 oktober 2011 om 14:00 uur in de Agnietenkapel van de Universiteit van Amsterdam Synthesis and biological evaluation Oudezijds Voorburgwal 231 of C2-substituted te Amsterdam 2A Na afloop van de promotie and A 6-trifluoromethylpurines zal hier tevens de receptie .
    [Show full text]
  • Abnormal Uterine Bleeding: Strategies for Management”
    PRE-CONGRESS COURSE 4 SIG Endometriosis & Endometrium “Abnormal uterine bleeding: strategies for management” CONTENTS Program overview p. 1 Speakers’ contributions • Abnormalities of menstrual bleeding: getting our terminologies right - I. Fraser (AUS) p. 3 • Abnormal uterine bleeding: the patient perspective - P. Warner (UK) p. 13 • Optimising strategies for evaluation and management of abnormal uterine bleeding - A. Prentice (UK) p. 32 • Unscheduled bleeding with exogenous hormone administration – P. Rogers (AUS) p. 33 • Strategies to control; endometrial bleeding - D. Archer (USA) p. 46 • Local mechanisms responsible for endometrial bleeding - H. Critchley (UK) p. 49 • Is there a role for selective progesterone receptor modulators in management of uterine bleeding? - K. Chwalisz (USA) p. 61 • Should menstruation be optional? – Health benefits of amenorrhoea – D. Baird (UK) p. 72 PRE-CONGRESS COURSE 4 - PROGRAMME SIG Endometriosis & Endometrium Abnormal uterine bleeding: strategies for management Course co-ordinators: H. Critchley (UK) & Th. D’Hooghe (B) Course description: Problematic uterine bleeding impairs quality of life for many women and often involves invasive treatments and significant cost. Agreement is needed on terminology and defi nitions in order to facilitate the establishment of multi-centre clinical trials evaluating the strategies for management. Contemporary management also requires an understanding of the patient’s perspective of her complaint and an understanding of acceptability to women of the available modes of investigation and treatment options. Optimal therapies will only be possible with a detailed understanding of the mechanisms involved in endometrial bleeding including unscheduled bleeding with exogenous hormone administration. Novel therapies need to be evaluated in the context of potential health benefits from therapies that reduce the number of menstrual cycles experienced by women.
    [Show full text]
  • Practice Parameters for the Treatment of Patients with Dominantly Inherited Colorectal Cancer
    Practice Parameters For The Treatment Of Patients With Dominantly Inherited Colorectal Cancer Diseases of the Colon & Rectum 2003;46(8):1001-1012 Prepared by: The Standards Task Force The American Society of Colon and Rectal Surgeons James Church, MD; Clifford Simmang, MD; On Behalf of the Collaborative Group of the Americas on Inherited Colorectal Cancer and the Standards Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons is dedicated to assuring high quality patient care by advancing the science, prevention, and management of disorders and diseases of the colon, rectum, and anus. The standards committee is composed of Society members who are chosen because they have demonstrated expertise in the specialty of colon and rectal surgery. This Committee was created in order to lead international efforts in defining quality care for conditions related to the colon, rectum, and anus. This is accompanied by developing Clinical Practice Guidelines based on the best available evidence. These guidelines are inclusive, and not prescriptive. Their purpose is to provide information on which decisions can be made, rather than dictate a specific form of treatment. These guidelines are intended for the use of all practitioners, health care workers, and patients who desire information about the management of the conditions addressed by the topics covered in these guidelines. Practice Parameters for the Treatment of Patients With Dominantly Inherited Colorectal Cancer Inherited colorectal cancer includes two main syndromes in which predisposition to the disease is based on a germline mutation that may be transmitted from parent to child.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Effects of a Novel Estrogen-Free, Progesterone Receptor Modulator
    Edinburgh Research Explorer Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women Citation for published version: Brache, V, Sitruk-Ware, R, Williams, A, Blithe, D, Croxatto, H, Kumar, N, Kumar, S, Tsong, Y-Y, Sivin, I, Nath, A, Sussman, H, Cochon, L, Miranda, MJ, Reyes, V, Faundes, A & Mishell, D 2012, 'Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women', Contraception, vol. 85, no. 5, pp. 480-8. https://doi.org/10.1016/j.contraception.2011.10.003 Digital Object Identifier (DOI): 10.1016/j.contraception.2011.10.003 Link: Link to publication record in Edinburgh Research Explorer Document Version: Peer reviewed version Published In: Contraception Publisher Rights Statement: NIH Public access author manuscript General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 26. Sep. 2021 NIH Public Access Author Manuscript Contraception. Author manuscript; available in PMC 2013 May 01.
    [Show full text]
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011
    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Mindy Goldman, MD Clinical Professor Dept
    Managing Menopause Medically and Naturally Mindy Goldman, MD Clinical Professor Dept. of Ob/Gyn and Reproductive Sciences Director, Women’s Cancer Care Program, UCSF Breast Care Center and Women’s Health University of California, San Francisco I have nothing to disclose –Mindy Goldman, MD CASE STUDY 50 yr. old G2P2 peri-menopausal woman presents with complaints of significant night sweats interfering with her ability to sleep. She has mild hot flashes during the day. She has never had a bone mineral density test but her mother had a hip fracture at age 62 due to osteoporosis. Her 46 yr. old sister was diagnosed with breast cancer at age 43, treated with lumpectomy and radiation and currently is doing well. There is no other family history of cancer. Questions 1. Would you offer her MHT? 2. If yes, how long would you continue it? 3. If no, what would you offer for alternative treatments? 4. Would your treatment differ if you knew she had underlying heart disease? Is it safe? How long can I take it? What about Mymy Bones?bones? Will it protect my heart? MHT - 2015 What about my brain? Will I get breast cancer? What about my hot flashes? Menopausal Symptoms Hot flashes Night sweats Sleep disturbances Vaginal dryness/Sexual dysfunction Mood disturbances How to Treat Menopausal Symptoms Hormone therapy Alternatives to hormones Complementary and Integrative Techniques Prior to Women’s Health Initiative Hormone therapy primary treatment of menopausal hot flashes Few women would continue hormones past one year By 1990’s well known
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]